The hybridization of EBV-immortalized human B-lymphocytes with a human-mouse heteromyeloma cell line.
The combination of Epstein-Barr-Virus (EBV)-permitted immortalization and somatic hybridization (fusion with a myeloma partner) may be the method of choice to produce human monoclonal antibodies. We show here that the fusion of EBV-infected human B-lymphocytes to the HAT-sensitive, ouabain-resistent heteromyeloma (human x mouse) fusion line CB-F7, resulted in stable growing hybridomas producing much more immunoglobulin than the parental lymphoblastoid lines. A more efficient clonability was shown for hybridoma cultures too. The loss of B cell markers (HLA-class II antigen, CD-22, CD-37) was detected. Limiting dilution experiments showed a better fusionability of IgM-producing EBV-transformed B cells in comparison to IgG-secreting counterparts.
Jahn
S
S
Institute of Medical Immunology, Humboldt University, Berlin.
Walper
A
A
Grunow
R
R
Heym
S
S
Volk
H D
HD
von Baehr
R
R
D000818:Animals; D000917:Antibody Formation; D015703:Antigens, CD / Q000032:analysis; D001402:B-Lymphocytes / Q000166:cytology*; D002455:Cell Division; D002459:Cell Fusion; D002460:Cell Line; D002472:Cell Transformation, Viral; D002999:Clone Cells; D004854:Herpesvirus 4, Human; D006801:Humans; D006825:Hybridomas / Q000166:cytology*; D007136:Immunoglobulins / Q000096:biosynthesis; D051379:Mice
D015703:Antigens, CD; D007136:Immunoglobulins